Following on from information provided to NICE by the company in September 2020 the appraisal of Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1390
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2020 the appraisal of Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 November 2020 | Suspended. Topic is suspended |
| 20 November 2020 | Note added to the project documents |
| 11 March 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of mogamulizumab for previously treated adult T-cell leukaemia-lymphoma. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual